Abstract
Treatment of heart failure (HF) is a challenging task. An impaired nitric oxide pathway contributes to several abnormal cardiac and vascular phenotypes typical of the failing cardiovascular system. Inhibition of phosphodiesterase-5 (PDE5) is a new therapeutic strategy for overexpressing nitric oxide signaling by increasing the availability of cyclic guanosine monophosphate (cGMP). A number of background studies support the use of PDE5 inhibitors in HF. Treatment of pulmonary hypertension secondary to left ventricular dysfunction appears to be a primary target by virtue of the high PDE5 selectivity for the pulmonary circulation. Basic studies suggest that increased cGMP activity by PDE5 inhibition has potentially favorable direct myocardial effects that may block adrenergic, hypertrophic, and proapoptotic signaling. Furthermore, studies in humans have underscored the benefits of acute PDE5 inhibition on lung diffusion capacity, systemic endothelial function, muscle perfusion, and exercise performance. Despite promising initial data, larger controlled trials are necessary to define the safety, tolerability, and potential impact of PDE5 inhibitors on morbidity and mortality across the wide spectrum of patients with HF.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005, 46:e1–e82.
Saraiva RM, Hare JM: Nitric oxide signaling in the cardiovascular system: implications for heart failure. Curr Opin Cardiol 2006, 21:221–228.
Palmer RM, Ashton DS, Moncada S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988, 333:664–666.
Kass DA, Champion HC, Beavo JA: Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 2007, 101:1084–1095.
Galiè N, Ghofrani HA, Torbicki A, et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148–2157.
Guazzi M, Samaja M: The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development. Curr Med Chem 2007, 14:2181–2191.
Takimoto E, Champion HC, Li M, et al.: Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005, 11:214–222.
Hassan MA, Ketat AF: Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol 2005, 5:10.
Takimoto E, Champion HC, Belardi D, et al.: cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 2005, 96:100–109.
Das A, Xi L, Kukreja RC: Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 2005, 280:12944–12955.
Fisher PW, Salloum F, Das A, et al.: Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005, 111:1601–1610.
Pérez NG, Piaggio MR, Ennis IL, et al.: Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction. Hypertension 2007, 49:1095–1103
Nagendran J, Archer SL, Soliman D, et al.: Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007, 116:238–248.
Borlaug BA, Melenovsky V, Marhin T, et al.: Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 2005, 112:2642–2649.
Al-Hesayen A, Floras JS, Parker JD: The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure. Eur J Heart Fail 2006, 8:864–868.
Guazzi M, Samaja M, Arena R, et al.: Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007, 50:2136–2144.
Lewis GD, Shah R, Shahzad K, et al.: Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007, 116:1555–1562.
Moraes DL, Colucci WS, Givertz MM: Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000, 102:1718–1723.
Gehlbach BK, Geppert E: The pulmonary manifestations of left heart failure. Chest 2004, 125:669–682.
Guazzi M: Alveolar-capillary membrane dysfunction in heart failure: evidence of a pathophysiologic role. Chest 2003, 124:1090–1102.
Guazzi M, Tumminello G, Di Marco F, et al.: The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004, 44:2339–2348.
Lewis GD, Lachmann J, Camuso J, et al.: Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007, 115:59–66.
Hirata K, Adji A, Vlachopoulos C, O’Rourke MF: Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 2005, 96:1436–1440.
Mahmud A, Hennessy M, Feely J: Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J Hum Hypertens 2001, 15:707–713.
Oliver JJ, Melville VP, Webb DJ: Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 2006, 48:622–627.
Katz SD, Balidemaj K, Homma S, et al.: Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000, 36:845–851.
Guazzi M, Casali M, Berti F, et al.: Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients. Clin Pharmacol Ther 2008, 83:336–341.
Hryniewicz K, Dimayuga C, Hudaihed A, et al.: Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. Clin Sci 2005, 108:331–338.
Chen Y, Traverse JH, Hou M, et al.: Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure. Am J Physiol Heart Circ Physiol 2003, 284:H1513–H1520.
Forfia PR, Lee M, Tunin RS, et al.: Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol 2007, 49:1079–1088.
Guazzi M, Reina G, Tumminello G, Guazzi MD: Exercise ventilation inefficiency and cardiovascular mortality in heart failure: the critical independent prognostic value of the arterial CO2 partial pressure. Eur Heart J 2005, 26:472–480.
Arena R, Myers J, Abella J, et al.: Development of a ventilatory classification system in patients with heart failure. Circulation 2007, 115:2410–2417.
Phillips BG, Kato M, Pesek CA, et al.: Sympathetic activation by sildenafil. Circulation 2000, 102:3068–3073.
Piccirillo G, Nocco M, Lionetti M, et al.: Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. Am Heart J 2002, 143:703–710.
Bocchi EA, Guimarães G, Mocelin A, et al.: Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002, 106:1097–1103.
Goldsmith SR: Type 5 phosphodiesterase inhibition in heart failure: the next step. J Am Coll Cardiol 2007, 50:2145–2147.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guazzi, M. Sildenafil and phosphodiesterase-5 inhibitors for heart failure. Curr Heart Fail Rep 5, 110–114 (2008). https://doi.org/10.1007/s11897-008-0018-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11897-008-0018-9